Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hypertension

An ACCOMPLISHED regimen for hypertension

At first glance, the findings of the ACCOMPLISH trial threaten to undermine the importance of diureticss in the arsenal of blood-pressure-lowering therapies. But closer examination reveals that the story is more complicated.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Kaplan–Meier curves for time to first primary composite end point in the ACCOMPLISH trial.

References

  1. Lewington, S. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903–1913 (2002).

    Article  Google Scholar 

  2. Turnbull, F. & the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362, 1527–1535 (2003).

    Article  CAS  Google Scholar 

  3. Jamerson, K. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417–2428 (2008).

    Article  CAS  Google Scholar 

  4. Chobanian, A. V. et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 289, 2560–2572 (2003).

    Article  CAS  Google Scholar 

  5. Turnbull, F. et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med. 165, 1410–1419 (2005).

    Article  Google Scholar 

  6. Dahlöf, B. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366, 895–906 (2005).

    Article  Google Scholar 

  7. Allemann, Y. et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J. Clin. Hypertens. 10, 185–194 (2008).

    Article  CAS  Google Scholar 

  8. Chrysant, S. G., Melino, M., Karki, S., Lee, J. & Heyrman, R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin. Ther. 30, 587–604 (2008).

    Article  CAS  Google Scholar 

  9. Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin–angiotensin system. J. Hypertens. 25, 951–958 (2007).

  10. Connor, J., Rafter, N. & Rodgers, A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull. World Health Organ. 82, 935–939 (2004).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Turnbull, F. An ACCOMPLISHED regimen for hypertension. Nat Rev Nephrol 5, 183–184 (2009). https://doi.org/10.1038/nrneph.2009.25

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2009.25

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing